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This paper presents commentaries on the microscopic morphology of esophageal squamous epithelium; the fre-
quency of duplication of the muscularis mucosae (MM) in Barrett’s esophagus (BE); the significance of multilayered
epithelium; whether cells in the lamina propria reflect those in the epithelium; how stem cells are identified in the
squamous esophagus; dilated intercellular spaces; the metastasizing potential of early carcinoma-dependent, molec-
ular or immunohistochemical tests that improve diagnosis; the role of immunohistochemistry IHC in grading of
neoplasia in Barrett’s esophagus and defining the risk of progression to adenocarcinoma; the roles of CDX1 and
CDX2 in squamous and cardiac mucosa; and the role of desmosomal cadherins and lectins in squamous and cardiac
mucosa.
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Concise summaries
 The embryonic esophagus is lined by two
distinct types of columnar epithelium before
squamous epithelium develops, which means
that esophageal squamous epithelium is ba-
sically a metaplasia that develops in colum-
nar epithelia that are maintained by fish,
amphibians, and some reptiles. It has common
patterns of reaction to different injuries. This
supposedly resistant epithelium is subject to a
variety of insults which it never was intended
to confront, the most common of which is re-
flux. In the normal esophagus, the intracel-
lular spaces are difficult to identify, but they
become very apparent in severe reflux injury,
inmany infections, and eosinophilic esophagi-
tis (EoE) may induce the most intense changes
in these spaces. The recently described lym-
phocytic esophagitis also has dilated spaces. It
is an embryonic metaplasia.
 Duplication of the muscularis mucosae (MM)
is not always present underlying Barrett’s
esophagus (BE) and, if it is present, may be
so focal that the finding cannot be expected to
be present in every slide.
 Multilayered epithelium is the most recent
term for a distinct subtype of epithelium at the
gastro-esophageal junction (GEJ) displaying
criteria of columnar and squamous epithe-
lium. The clinical significance of multilayered
epithelium rises and falls with a possible con-
nection or precursorship to BE. Detailed stud-
ies on cytokeratins and mucins expressed by
multilayered epithelium and the surrounding
epithelia were also interpreted as indications
that multilayered epithelium is a precursor
doi: 10.1111/nyas.12241
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lesion of BE based on the findings that
cytokeratin-14 was virtually missing in mul-
tilayered epithelium and CDX-2 and mucin
2 was detected in almost half of the cases,
whereas the presence of cytokeratin 19 was
interpreted as possible squamous stem cell
marker but with much lesser evidence for a
cardia stem cell source. After careful analysis
of cytokeratins and mucins, multilayered
epithelium needs to be seen as metaplastic
epithelium sharing characteristics mainly with
bronchial epithelium.
 We know little about the normal lamina pro-
pria. Normal lamina propria contains en-
dothelial cells lining vessels, fibroblasts, and/or
myofibroblasts. Mucus gland cells and their
ducts are present especially distally, and the
ducts of submucosal glands also pass through
the lamina propria. The lamina propria is vir-
tually always ignored when the main epithelial
diseases, with which we deal, including neo-
plasms or inflammation, are discussed. Sub-
stantial information on lamina propria in EoE,
reflux disease, or BE is still lacking today.
 Support for thepresenceof adult stemcell pop-
ulations in the human esophageal ducts and
submucosal glands comes fromclinical and ex-
perimental investigations. Provocative experi-
ments provide new evidence for the important
role of p63, both a suppressor and a transcrip-
tional activator of groups of genes involved
in the program of epithelial development, in
maintaining squamous epithelia, and for the
possible substitution of an alternative source
of cell renewal of an adult tissue if its usual
stem cell population is inactivated or injured.
Given important anatomical and physiologi-
cal differences between the animal and human
esophagus, additional work is needed to refine
our understanding of possible stem cell popu-
lations in the esophagus, and their role in the
renewal of normal squamous epithelium.
 Change in commitment of multipotent stem
cells not only explains the variety of cellular
phenotypes in BE, as well as the regeneration
of squamous epithelium after endoscopic re-
moval of Barrett’s mucosa, but also offers a
possible key mechanism for the inherent can-
cer risk of BE. The exact location of the stem
cells in the esophagus remains a topic of dis-
cussion: interpapillary basal layer cells demon-
strate higher proliferation and clonogenic ca-
pability, but only display very low expression
of 1-integrin, which is not in line with mul-
tipotent stemness, as undifferentiated cells lose
1-integrin expression when they commit to
terminal differentiation.Other groups have lo-
cated the esophageal stem cells outside the ep-
ithelium. In this perspective, and similar to the
bulge region of hair follicles, the submucosal
gland ducts may be very important. Of inter-
est, it has also been suggested that BE could be
the result of bone marrow–derived stem cells.
 Dilated intercellular spaces (DIS), an increase
in the space between squamous cells, were first
reported in human esophageal epithelia of pa-
tients with symptoms of esophagitis, and the
current hypothesis is that they induce higher
activation of the sensory nerve endings. They
are associated with symptoms of reflux, even
more so than other histologic parameters, and
seem to disappear with resolution of symp-
toms after treatment.
 Epithelial damage brought on by even stress
alone can dilate the intercellular spaces. They
are also observed in EoE, but with a different
pattern. However, the presence of DIS, when
taken in context including clinical presenta-
tion and other histologic features, is a sensitive
marker of GERD.
 MMduplication is overall very frequent in BE,
but it can be patchy. In Barrett’s adenocarci-
noma, the exact depth of invasion into the du-
plicated MM neither influences lymph node
metastasis nor does it appear to affect survival.
Themain reason to recognizeMMduplication
vis-a`-vis esophageal adenocarcinoma (EAC) is
to avoid the trap of overstaging.
 For the diagnosis of BE, finding goblet cells
on hematoxylin and eosin (H&E) is pretty
easy, because in this stain, goblet cells are gray
or faintly blue compared to the gastric type
columnar cells, which are pale pink. A mucin
stain, such as an Alcian blue, will stain the
goblet cells an intense blue, but this stain also
uncovers cells that might be misinterpreted as
goblet cells. As for Barrett’s complications, the
criteria for the dysplasias are not clear-cut, so
reproducibility is poor, especially at the lower
end of the dysplasia spectrum. Several markers
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have been studied in dysplasias including
-methylacyl coenzyme A racemase
(AMACR). However, the diagnosis of
low-grade dysplasia by itself is not as impor-
tant as the diagnosis of low-grade dysplasia
accompanied by positive p53 as an indication
of progression risk. The marker studies are
based on diagnoses made on slides stained
with H&E. Because the diagnoses were already
known, it is obvious that the markers offered
no better diagnostic information, possibly
except for p53 staining of H&E diagnosed
low-grade dysplasia. At this moment, there
are no molecular or immunohistochemical
tests that improve diagnosis and management
compared with H&E-stained biopsies and
surveillance.
 Potentially useful antibodies that might im-
prove sensitivity and specificity of detec-
tion of intraepithelial neoplasia (dysplasia)
and adenocarcinoma include those recog-
nizing p53, p16INK4A, c-erbB2, cyclin D1,
p27KiP1 EGFR, COX-2, -catenin, Rab11a,
CD1a, HER2, EGFR, SMAD4, IMP3, Ki-67,
Serpins, and AMACR. However, evidence to
support consistently positive and negative pre-
dictive values of any potentially useful marker
awaits larger series, and several fundamental
challenges limit clinical applicability of cur-
rently reported immunohistochemical mark-
ers. Currently, no single marker or panel is
clearly predictive of risk to progression to EAC,
and it remains unclear if immunohistochem-
ical staining adds clinical value over the gold
standard of histological grading and review by
a second experienced pathologist.
 Given the fact that Barrett mucosa is intesti-
nalized, investigators correctly anticipated rel-
evanceof the transcription factors (TFs)CDX1
and CDX2, which participate in intestinal
development and maintain the intestinal phe-
notype. Several groups have shownCDX2pro-
tein expression, as detected by immunohisto-
chemistry (IHC), in virtually all biopsies of
Barrett epithelium (i.e., columnar epithelium
with goblet cells proximal to the anatomic
GEJ). Different bile acids may variably acti-
vate the CDX2 promoter in cell lines, with
dehydrocholic acid (DHCA) and cholic acid
(CA) achieving the greatest induction. How-
ever, Cdx2 expression alone is insufficient to
produce the full Barrett phenotype owing,
in part, to epigenetic regulation of the adult
genome. Furthermore, although Cdx2 expres-
sion results in reduced proliferation, this fea-
ture must be overcome by some other factors,
as BE, even without dysplasia, is proliferative.
Expression microarrays have identified hun-
dreds of genes differentially expressed in BE
relative to esophageal squamous epithelium.
These include three HOXB family TFs, which,
in transfection experiments, are also able to in-
duce the expression of intestine-specific pro-
teins. Increased expression of these HOXs
occurs in the setting of activating histonemod-
ifications and chromatin decompaction.
 Changes in desmosomal cadherins, the adhe-
sion molecules of the adhesive intercellular
junction proteins, contribute to the pathogen-
esis of GERD in the cardia mucosa. Lectins
are a structurally heterogeneous group of
carbohydrate-bindingproteins that arepresent
in normal, inflamed, and neoplastic mucosa,
but composition may change according to
the underlying condition. As Lectin UEA-I-
binding proteins were specifically increased in
the squamous epithelium of patients with BE,
some authors concluded that it may serve as a
potential marker for BE, especially in patients
with short-segment BE. However, even if var-
ious studies have shown that the expression
of cadherins and lectins is altered in GERD
and BE, these markers are currently only of
scientific interest.
1. The microscopic morphology of
esophageal squamous epithelium
Henry D. Appelman
appelman@umich.edu
Because this topic is part of a symposium devoted
to esophageal tissue resistance, I assume that this
discussion relates to how the squamous epithelium
of the esophagus resists injury, or how it fails to do
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so. The normal squamous mucosa has thick layers
of superficial squamous cells full of glycogen which
make the cytoplasm look clear. There are thin lay-
ers of basal cells and short lamina propria papillae
surrounded by basal cells. Stratified squamous ep-
ithelium is well suited to those areas of the body
subject to constant abrasion because it is thick, and
layers can be sequentially sloughed off superficially
and replaced before the deeper tissues are exposed.
This is great information, but how did our esoph-
agus get its squamous lining? During embryonic de-
velopment, the esophagus is initially lined by a thin
layer of stratified columnar epithelium, which pro-
liferates to almost include the lumen.1–3 At approx-
imately 6–7 weeks gestation, the lumen is reformed
as a result of vacuoles forming in these columnar
cells. As early as 8 weeks, beginning in the middle
third, ciliated cells appear and extend proximally
and distally to almost cover the entire stratified
columnar epithelium. At about 5 months, stratified
squamous epithelium initially appears, also start-
ing in the middle third, and this epithelium extends
proximally anddistally, replacing the ciliated epithe-
lium. Therefore, the embryonic esophagus is lined
by two distinct types of columnar epithelium be-
fore squamous epithelium develops, which means
that esophageal squamous epithelium is basically a
metaplasia. What were the stimuli that produced
the squamous metaplasia and why did the squa-
mous epithelium replace the two columnar types?
None of the sources tell us what was wrong with the
columnar epithelium. Teleologically, it is said that
stratified squamous epithelium lines the esophagus
because it is very protective, especially as we eat
crusty and hot foods. However, this epithelium is a
problem formaintenance. These are nonkeratinized
surfaces, in contrast to the skin, and they must be
keptmoist bybodily secretions toprevent themfrom
drying and dying. Presumably, that is why we have
the submucosal and lamina propria mucus glands.
We know quite a lot about the esophageal ep-
ithelium inmore primitive vertebrates.4 Eels, perch,
sharks, rays, and skates have ciliated epithelia. The
most advanced sport and commercial fish have
columnar epithelia with a few mucus cells. Fresh-
water fish have stratified squamous epithelia with
numerous mucus cells. Amphibians have ciliated
epithelia, and esophageal epithelia in reptiles vary
from group to group. For instance, lizards have cil-
iated columnar epithelia with goblet cells whereas
turtles have heavily keratinized squamous epithelia,
which presumably protect the mucosa from the tur-
tle’s abrasive diet that includes spiculated sponges
and jellyfish. Birds have stratified squamous epithe-
lia. They also have an abrasive diet that is heavy in
roughage.
This supposedly resistant epithelium is subject to
a variety of insults, which it never was intended to
confront, themost commonofwhich is reflux. Stud-
ies on in vivoperfusion of the esophaguswith acid or
acid and bile acids suggest that there is dilatation of
the intracellular spaces in the squamous epithelium,
something also referred to as spongiosis in the skin.
We can actually see this in biopsies.5–8 In the nor-
mal esophagus, the intracellular spaces are difficult
to identify, but they become very apparent in severe
reflux injury and in many infections, and EoE may
induce themost intense changes in these spaces. The
recently described lymphocytic esophagitis also has
dilated spaces.
Another common response to injury is expansion
of the proliferative zone, the basal cells, and this
expansion can be identified as piling up of basal
cells and/or lengthening of the papillae, which carry
with them multiple layers of basal cells higher into
the superficial squamous epithelium.
In summary, the microscopic morphology of the
esophageal squamous epithelium seems to relate to
what bangs against it. It is well suited to mucosa
subject to constant abrasion. It has evolutionary
overtones, namely, it is present in some fish but
not amphibians, some but not all reptiles, all birds
and allmammals. It is an embryonicmetaplasia that
develops in columnar epithelia that are maintained
by fish, amphibians, and some reptiles. It has com-
mon patterns of reaction to different injuries that
were probably never supposed to bother it. Regard-
less, it seems to be a good epithelium for people in
general, and especially for gastroenterologists and
pathologists who deal with it on a daily basis.
2. Frequency of duplication of the MM
in BE
Catherine Streutker
streutkerc@smh.ca
Are there always two layers in BE? If not, how do
we know when we are definitively in the submu-
cosa? The presence of dual layers of MM underly-
ing segments of BE has been recognized since the
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1980s,9–12 however, the majority of papers noting
this change focus on the issues arising from the
presence of a duplicated MM (dMM) rather than
the incidence of the change. The few papers that
do note the rate of finding these dual layers show
considerable variability.10–18 In papers looking at
esophagectomy specimens, dMM is found in 46–
100% of specimens10–16; a rough average from these
patients gives 79% of specimens containing dMM.
The rare papers on mucosal resection specimens
(EMRs) show a lesser proportion with dMM, with
46% and 66% containing dMM.17,18 A review of
106 recent EMR cases from 30 patients in my center
identified at least focal dMM in 101 (95%) of cases.
This focality raises a second point: several studies
have noted that, even though dMM is present at
some point along the segment of BE, this may be
quite patchy. In esophagectomy specimens, the pro-
portion of the BE segment showing dMM ranged
from 5% to 90% (mean of 44%)14 in one study, and
70% to 90% in another.12 In EMR specimens, ex-
tensive duplication was present in 38% of the spec-
imens, moderate in 33%, and minimal in 29%.18
Another EMR study showed 46% of specimens had
focal or extensive dMM (10–100%), wheras 54%
had minimal (<10%) or absent dMM.17 These re-
sults demonstrate that dMM is not always present,
and if it is present may be so focal that the finding
cannot be expected to be present in every slide. This
is further complicated by reports of occasional trip-
lication of the MM and cases with thickened single
layers of MM.14 Considering this, how can we be
sure that we are looking at submucosal tissues? The
presence of submucosal glands is, by definition, in-
dicative of the presence of submucosal tissue. How-
ever, these glands are scattered along the esophageal
length and are not present in every slide. Also, EMR
specimens often have a considerable curvature from
muscle contracture, which can make the plane be-
tween the deepest layer of the MM and the sub-
mucosa difficult to evaluate even when submucosal
glands are present.Hahn et al.19 noted that the tissue
between the dMM layers had characteristics of the
BE lamina propria, with delicate, thin-walled blood
vessels. The submucosa, in contrast, characteristi-
cally has robust, thick-walled muscular arteries,16
which are often easily identified on slides, even in
EMRspecimens (Fig. 1).We also tend to assume that
early carcinomas of the upper gastrointestinal tract
donot induce stromal desmoplasia until they invade
Figure 1. Adenocarcinoma invasive into the submucosa ad-
jacent to a submucosal gland and a thick-walled artery. Early
changes of stromal desmoplasia are present.
into the submucosa; this is poorly documented, but
there are at least anecdotal cases of intramucosal
carcinomas with stromal desmoplasia.14,16
Overall, dMM is not always present underlying
BE. This can make detection of the submucosal tis-
sues difficult: the presence of submucosal glands and
thick-walledmuscular vessels are themost definitive
indicators of the presence of the submucosa, while
the presence of desmoplasia may also be of use but
requires further study.
3. What is the significance of
multilayered epithelium?
Michael Vieth and Helmut Neumann
pathologie@klinikum-bayreuth.de
Background
Multilayered epithelium is the most recent term for
a distinct subtype of epithelium at the GEJ display-
ing criteria of columnar and squamous epithelium.
In the literature and daily routine practice there are
some synonyms available for so-called multilayered
epithelium: pseudostratified metaplasia, hybrid ep-
ithelium. Without any doubt, squamous metapla-
sia with reserve cell hyperplasia,20 multilayered
epithelium,21,22 and pseudostratified metaplasia23
are good expressions in terms of self-explanatory
terms. The first description is from 1981.20 In 1993
the findings of a distinctive esophageal surface cell at
the GEJ were confirmed by electron microscopy.24
Because multilayered epithelium was found in pa-
tients with BE, authors21,22,24 speculated whether
multilayered epithelium is a precursor for BE. This
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is in accordancewith another publication25 showing
thatmultilayered epithelium is believed to represent
at least a histological marker of reflux disease.
Available data
The clinical significance of multilayered epithelium
rises and falls with a possible connection or precur-
sorship to BE because BE is a precancerous condi-
tion and may need additional clinical follow-up.
Multilayered epithelium was described in detail
in 2001 by Glickman et al.22 as four to eight layers of
cells with nuclear pseudostratification, mean length
of 40 m (20–100 m), with suprabasal and su-
perficial layers being more columnar, and most im-
portantly, missing intercellular spaces/bridges that
are found in normal squamous epithelium. The
majority is commonly found in surface epithelium
(76%). Adjacent epithelium was described as cardia
in 77%, goblet cell–containing epithelium in 23%,
and intestinal-type epithelium elsewhere in 100%.
The two latter are the reasons that a discussion was
started seeing multilayered epithelium as a precur-
sor of goblet cell–containing Barrett’s epithelium.
Quite often (76%), cilia can be identified at the
surface layer of multilayered epithelium. The first
descriptions are found by Okuda et al. in 1976,
Torikata et al. in 1989, and Rubio et al. in 1990.26–28
Detailed studies on cytokeratins22 and mucins25
expressed by multilayered epithelium and the sur-
rounding epithelia were also interpreted as indi-
cation that multilayered epithelium is a precursor
lesion of BE based on the findings that cytokeratin-
14 was virtually missing in multilayered epithelium
and CDX2 and mucin 2 was detected in almost half
of the cases, whereas the presence of cytokeratin-
19 was interpreted as possible squamous stem
cell marker but due to the missing cytokeratin-14
with much lesser evidence for a cardia stem cell
source.
On the other hand, Takubo et al.23 published a
detailed analysis of cytokeratins and found CK10,
CK14, CK20 negative and CK4, CK7, CK8, CK13,
CK18, and tubulin positive. These findings after cy-
tokeratin analysis were interpreted as multilayered
epithelium being a type of metaplasia that shares a
lot with bronchial epithelium but being no distinct
precursor lesion of Barrett’s. The prevalence ofmul-
tilayered epithelium in this study was given as 49%.
Thirty-one percent of the cases showed ciliated cells.
Shields and Glickman21,22 found a much smaller
prevalence ofmultilayered epithelium in their series
(13–24%).
The frequency of multilayered epithelium in a
normal population is still under discussion. Our
unpublished data show an average of 5% in pa-
tients with and without reflux disease and with and
without Barrett’s epithelium. If this distribution is
indeed representative, this has to be considered as
a strong argument against multilayered epithelium
being a precursor lesion of BE. This is also in line
with a publication from Takubo et al.,20 who first
described multilayered epithelium as a kind of cili-
ated squamous epithelium. It has to be noticed that
Barrett’s epithelium and reflux disease are rarely
found in Asian populations.
Conclusion
In conclusion, multilayered epithelium seems not
to represent a precursor of BE, and its prevalence
is much smaller than previously anticipated. After
careful analysis of cytokeratins and mucins, mul-
tilayered epithelium needs to be seen as metaplas-
tic epithelium sharing characteristics mainly with
bronchial epithelium.
4. Do cells in the lamina propria reflect
those in the epithelium?
Henry D. Appelman
appelman@umich.edu
In order to answer this question, we have to know
what cells are in both normal and abnormal epithe-
lium and lamina propria. In the normal esophagus,
the squamous epithelium and the lamina propria
are separate, discrete layers. We know little about
the normal lamina propria. The biopsies we re-
ceive in routine practice generally capture very lit-
tle of it. Resected specimens have esophageal dis-
eases, so the resected lamina propria may not be
a good source of normal. Normal lamina propria
contains endothelial cells lining vessels, fibroblasts,
and/or myofibroblasts. Mucus gland cells and their
ducts are present especially distally, and the ducts
of submucosal glands also pass through the lam-
ina propria. Information from three textbooks, two
from 2007 and one from 2008, suggests that the
normal lamina propria contains scattered inflam-
matory cells, mostly T lymphocytes, some plasma
cells, mostly IgA-producing and occasional lym-
phoid follicles around ducts or where ducts were
obliterated.1–3
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The cells in the normal squamous epithelium,
also as defined in three recent textbooks, include T
lymphocytes, Langerhans cells, and inone reference,
a few neutrophils and basophils.
What happens to the cell make-up of the lamina
propria in diseases?
The diseases with which we deal are mainly
epithelial, including neoplasms and inflamma-
tion, including those that are reflux induced
and infectious. Peculiarly, in the textbooks and
in the literature, the lamina propria is virtually
always ignored when these diseases are discussed.
For instance in candidiasis, the fungi invade the
epithelium from the lumen and often cause striking
inflammatory changes in the epithelium including
neutrophils, even with small abscesses. In contrast,
Herpes virus, which effects squamous epithelium
from inside, induces very little intraepithelial in-
flammation. There is remarkably little information
about what happens to the lamina propria in these
infections except perhaps a passing mention of a
few neutrophils. It is virtually impossible to find
an illustration of the lamina propria in these infec-
tions in any textbooks. Cytomegalovirus involves
endothelial cells of lamina propria so the textbooks
hone in on that, probably because the infected cells
with the nuclear and cytoplasmic inclusions are so
photogenic. But there is also accompanying inflam-
mation, and hardly any textbooks pay attention
to that inflammation. Peculiar macrophages in the
lamina propria were identified in both herpesvirus
and cytomegalovirus infections.
How about EoE? Most of the biopsies that we see
in this condition have no lamina propria, only ep-
ithelium.However,whenwedo get laminapropria it
tends to be full of collagen and the cells that form it.
Fibrosis is a common complication of EoE, so pre-
sumably these collagen-forming cells in the lamina
propria reflect the eosinophils in the epithelium.
How about reflux disease? There are likely to be
more lymphocytes and scattered eosinophils and
neutrophils in the epithelium, but the only infor-
mation in textbooks and the literature about lamina
propria changes in reflux have to do with ulcers
and squamous changes at the margins. Yet there are
likely to be changes of chronicity with plasma cells
in the lamina propria at the base and edges of some
of these ulcers.
In Barrett’s mucosa, the lamina propria and
the epithelial structures are mixed, which means
the lamina propria always is present in a biopsy.
Barrett’s mucosa almost always has some lamina
propria plasma cells, in other words, chronic in-
flammation, and the number varies widely from
patient to patient. But the textbooks and literature
ignore the lamina propria to concentrate on the
epithelium. One study, published only in abstract
form, suggested that lamina propria inflammation
was due to reflux, but as far as I can tell, the results
of this study were never published.
In summary, the answer to the question, “Do cells
in the lamina propria reflect those in the epithe-
lium?” is that there is just not enough published
information to answer this question. Maybe it is
time to do a definitive study on the lamina propria
in esophageal diseases. We eagerly await the results
of that study.
5. How are stem cells identified in the
squamous esophagus?
Melissa P. Upton
mupton@uw.edu
What is a stem cell?
Stem cells are defined as unspecialized cells that are
self-renewing, able to generate an amplified popula-
tion with asymmetric cell division and slow-cycling
growth. Other essential properties include the
ability to retain telomere length, resist apoptosis,
and serve as a cell-population source for renewal of
a tissue over the lifetime of an organism. Stem cells
are capable of dividing and renewing themselves
for long periods, and through asymmetric cell
division they may give rise to specialized cells that
differentiate. Embryonic stem cells can give rise to
all three types of adult tissues, whereas adult stem
cells are thought to give rise to tissues where they
reside.29,30
What are the putative sources of esophageal
stem cells?
Possible candidates include the basal zone of the
squamous epithelium, submucosal gland ducts,
submucosal glands, and circulating stem cells of
bone marrow origin. This review will focus on pu-
tative adult stem cells located in the esophagus itself,
not addressing a potential role of circulating bone
marrow stem cells.
In experimental models, stem cells have the
ability to exclude Hoechst 33342 DNA-binding
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dye mediated by the ABCG2 transporter and to
retain tritiated-thymidine labeling after bromod-
eoxyuridine (BRDU) treatment, indicative of slow
cycling. Rustgi et al. detected a cell population
with these characteristics in the basal epithelium
of the squamous epithelium in a mouse model.30
Unlike humans, however, mice lack esophageal
submucosal glands. Therefore, while providing
evidence for a possible adult stem cell population
in the basal zone of the squamous epithelium, a
mouse model cannot address whether there are
stem cell populations in ducts and submucosal
glands of the human esophagus.
Nonetheless, because the esophageal squamous
lining is an analog of the skin, and because sub-
mucosal ducts have some similarity to the sweat
glands and hair follicles of the skin, it is reason-
able to review the results from Elaine Fuchs and
team regarding skin renewal and stem cells in a
murine model. Different populations of cells that
meet the criteria for adult stem cells were detected
in the basal zone of the epidermis, at the isthmus
of the hair follicle, and at the hair follicle bulge.30,31
These locations are anatomically similar to the squa-
mous basal zone of the esophagus, esophageal duct,
and submucosal gland; therefore, similar separate
adult stem cell populations may be present in these
analogous regions in the human esophagus. In addi-
tion, there is evidence for themigratory capability of
hair follicle and bulge cells, and for their contribu-
tion to epidermalhealing following injury.32 Human
esophageal duct and submucosal gland populations
might have similar capabilities tomigrate and repair
the esophageal mucosa.
Support for the presence of adult stem cell popu-
lations in the human esophageal ducts and submu-
cosal glands comes from clinical and experimental
investigations.During endoscopy, squamous islands
are commonly observed in the midst of columnar-
lined esophagus; histological examination confirms
the location of these squamous islands in associ-
ation with ducts from submucosal glands.33 Two
studies from the laboratory of NicholasWright pro-
vide experimental evidence of stem cell populations
in theducts and submucosal glands.Theyused laser-
capture microdissection and loss-of-heterozygosity
studies to identify the same somatic mutation in
a clone of BE and in the adjacent normal squa-
mous duct.34 Later, they demonstrated that neo-
squamous islands comprised clonal patches of cells
sharing the same mitochondrial DNA mutation as
adjacentBarrett epithelial glands and theunderlying
duct cells.35
Finally, a p63 knockout mouse model has also
provided new insights into esophageal renewal and
putative stem cells. p63 is a homolog of the p53
tumor suppressor gene, expressed in stem cells of
skin, breast, and prostate, and involved in morpho-
genesis and maintenance of all stratified epithelia.
p63 appears to be both a suppressor and a tran-
scriptional activator of groups of genes involved in
the program of epithelial development. Although it
is essential for stem cell regeneration in stratified
squamous epithelia, it is not necessary for lineage
differentiation in a nonsquamous direction. Mice
in which p63 has been knocked out lack continu-
ous epidermis and exhibit disrupted development
of squamous epithelia. They also have thymic hy-
poplasia. Epithelial cells in culture that lack p63 are
deficient in their ability to grow in clones.36
Examination of the esophagi from p63 knock-
out mice revealed a diminution of p63+ cells in
the basal zone of the squamous epithelium. Follow-
ing programmed damage to the squamous-lined
esophagus, residual putative embryonic stem cells
at the EGJ migrated into the distal esophagus, ac-
companied by the development of columnar meta-
plasia of the distal esophagus.37 p63 null mice also
failed to undergo the normal transition in embryo
from columnar-lined to squamous-lined esopha-
gus. These provocative experiments provide new ev-
idence for the important role of p63 in maintaining
squamous epithelia and for the possible substitu-
tion of an alternative source of cell renewal of an
adult tissue if its usual stem cell population is inac-
tivated or injured. They also raise new ideas about
the role of the GEJ reserve or stem cell popula-
tion in BE, and for the important developmental
role of p63 in orchestrating developmental changes
in esophageal development. Given the absence of
submucosal glands in mice, however, there remain
important unanswered questions about the role of
stem cells (and of p63) in submucosal glands and
ducts in humans in the setting of chronic reflux,
esophageal injury, and repair.
In conclusion, how are stem cells identified
in the squamous esophagus?
Research efforts have used animalmodels, including
the p63 knockout model, cell-culture models, and
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laser-dissection mapping of patches of epithelium
that share commonmitochondrial DNAmutations.
Given important anatomical and physiological dif-
ferences between animal and human esophagi, ad-
ditional work is needed to refine our understanding
of possible stem cell populations in the esophagus,
their role in renewal of normal squamous epithe-
lium, and the ways that normal renewal is disrupted
in associationwith acid and bile reflux, or in embry-
onic development, to result in columnar metaplasia
and BE.
6. Can stem cells be identified in Barrett’s
dysplasia?37–45
Xavier Sagaert
xavier.sagaert@uzleuven.be
The human esophagus is lined by a nonkeratiniz-
ing stratified squamous epithelium. In response to
chronic GERD, this multilayered epithelium can
be replaced by a single layer of columnar, usually
mucus-secreting, epithelium (a process called Bar-
rett’s metaplasia). Differentiation of the Barrett’s
metaplastic epithelium may be of either gastric or
intestinal phenotype, and is therefore histologically
subclassified into these two subtypes, although in-
ternationally the definition of BE tends to be re-
stricted to the intestinal phenotype (withpresenceof
goblet cells). BE is a predominant risk factor for the
development of adenocarcinoma (30- to 50-fold in-
creased risk in comparison with the general public).
This has major clinical implications, as esophageal
cancer is a common cause of malignancy-related
death, accounting for more than 500,000 deaths per
year worldwide.
Initially, it was believed that Barrett’s metaplasia
was the result of upwardmigration fromtransitional
zone cells of the GEJ,38 but this could not explain
the development of columnar epithelium in artifi-
cially defective mucosa above a squamous barrier
in animal models. A second hypothesis, a metaplas-
tic conversion from fully differentiated squamous
epithelium into a columnar epithelium (so-called
transdifferentation40)was dismissed by the observa-
tion that squamous epithelium may redevelop after
endoscopic removal of Barrett’s epithelium. Hence,
a third hypothesis recently gained a lot of interest,
being that BE is the consequence of change in com-
mitment ofmultipotent stem cells. This not only ex-
plains the variety of cellular phenotypes in Barrett’s
epithelium and the regeneration of squamous ep-
ithelium after endoscopic removal of Barrett’s mu-
cosa, but also offers a possible key mechanism for
the inherent cancer risk of BE, as multipotent stem
cells have been implicated in carcinogenesis in other
organs (e.g., colon).41
However, the exact locationof the stemcells in the
esophagus remains a topic of discussion. Most evi-
dently, and in analogy to the epidermis of the skin,
one would expect the stem cells to be located in the
basal layer of the epithelium. This is in line with ob-
servations in mouse models, where a CD34+ stem
cell populationwas identified in the esophageal basal
layer43 (although thehistology of human esophageal
epithelium is remarkably different from that of
mouse, with the latter lacking papillae). Data on the
exact location of basal layer stem cells (at the top of
papillae vs. interpapillary) are conflicting:41,42 inter-
papillary basal layer cells demonstrate higher pro-
liferation and clonogenic capability (making them
excellent stem cell candidates), but only display very
low expression of 1-integrin, which is not in line
with mutipotent stemness, as undifferentiated cells
lose 1-integrin expression when they commit to
terminal differentiation.
Other groups have located the esophageal stem
cells outside the epithelium. In this perspective,
and similar to the bulge region of hair follicles, the
submucosal gland ducts may be very important.
Because their proximal two-thirds are lined by a
columnar epithelium, and their distal third by a
squamous epithelium, the glandular neck region
of these glands has been suggested as the location
for Barrett’s stem cells.43 This gland duct theory is
supported by several findings:44 (1) histological
evaluation revealed that gland ducts frequently
open on to the surface of Barrett’s epithelium;
(2) immunohistochemical similarities have been
found between submucosal glands and Barrett’s
epithelium in pig tissues and cell cultures; (3) a
p16 mutation was found in common between sub-
mucosal glands and adjacent Barrett’s epithelium;
and (4) islands of neo-squamous epithelium were
found to be wild type at loci containing mutations
within the adjacent Barrett’s epithelium. More
recently, using nonpathogenic mitochondrial DNA
mutations as clonal markers, it was found that Bar-
rett’s metaplastic glands are indeed clonal, contain
multiple stem cells, and share a common squamous
progenitor.37
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Of interest, it has also been suggested that BE
could be the result of bone marrow–derived stem
cells.45
7. Are DIS normal?
Helen H. Wang
hwang@bidmc.harvard.edu
DISwere first reported in human esophageal epithe-
lia of patients with symptoms of esophagitis.46,47
They have subsequently been shown in in vitro ex-
perimental and in vivo esophageal perfusion studies.
They were detected on transmission electron mi-
croscopy (TEM) with or without computer-assisted
morphometry,48 as well as on light microscopy
(LM).49 A summary of the findings of DIC and
its association with nonerosive and erosive reflux
disease in the literature is shown in Table 1.8 Inmost
studies, a statistically significant difference was
found in intercellular spaces as measured by TEM
between patients with reflux disease and control
subjects.50 DIS can be experimentally induced in
humans by acid or acid–pepsin51 and in animals
(mostly rabbits) by acid or acid–pepsin, bile acid re-
gardless of pH,52 hypertonic solutions, or stresswith
or without acid–pepsin.8 The current hypothesis
is that DIS induces higher activation of the sensory
nerve endings. Symptom score has been found
to be most strongly associated with DIS of all the
histological parameters (DIS, basal cell hyperplasia,
papillary elongation, necrosis/erosion, eosinophils,
and neutrophils) of GERD.53 A few studies have
shown a response (reversibility) to treatment for
GERD.54
In summary, DIS is nonspecific and is seen in up
to 30% of asymptomatic subjects and in nonreflux
esophagitis patients. However, DIS is seen in much
higher rates, up to 94%, of patients with GERD.
An association has been found between DIS and
exposure to acid, acid–pepsin, bile, and stress (both
experimentally and empirically). It appears to be as-
sociatedwith symptomsof reflux, evenmore so than
other histologic parameters, and appears to disap-
pear with resolution of symptoms after treatment.
8. Why and when do DIS occur?
Hala El-Zimaity
Hala.el-zimaity@uhn.ca
GER is common in healthy subjects with no symp-
toms. GERD, a common disorder in the West-
ern world, occurs when reflux lasts more than a
few minutes, and disrupts the physiologic circa-
dian rhythm55 causing symptoms and (or) com-
plications. Some patients experience heartburn and
esophageal erosions, but for others the disease may
get complicated with esophageal strictures, Barrett’s
metaplasia, and adenocarcinoma.
Importantly, EAC incidence has increased in the
past 20 years,56 yet most patients with GERD have
no symptoms and endoscopy is often negative.57
Given that the risk of esophageal damage and BE in-
creases with higher reflux levels, pathology is often
used to evaluate patients. Before 1979, the histology
Table 1. Summary of the presence of DIS and its association with nonerosive (NERD) and erosive (ERD) reflux
disease
Author, year Method NERD ERD Control
Solcia, 2000 LM & EM 68% 90% 8%
Villanacci, 2001 LM 71% 100% –
Vieth, 2004 LM 56% Red streak: 91% –
Bove, 2005 LM-before (B) versus after
(A) acid perfusion
B: 80%
A: 70%
B: 86%
A: 86%
B: 22%
A: 44%
Zentilin, 2005 LM pH+: 83%
pH–: 67%
94% 30%
Takubo, 2005 LM E Ca: 33% 48% 21%
Autop: 0%
Ravelli, 2006 LM (% area) 2.21 + 2.60% (5% in nonreflux
esophagitis)
0.44 + 0.13%
LM, light microscopy; EM, electron microscopy; E Ca, esophageal cancer; Autop, autopsy.
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Figure 2. (A) GERD, the DIS are mainly basal, H&E 10×.
(B) Markedly DIS in all three layers are more often noted with
EoE, H&E 10×.
features most often used included basal cell hyper-
plasia, papillae elongation, and any inflammation
(eosinophils, lymphocytes, and neutrophils); these
features have limited sensitivity and specificity.58
DIS are considered as a more sensitive marker of
GERD (Fig. 2A).59 Hopwood et al. first defined it
using electron microscopy50 as greater than 0.47–
2.4 mm, mainly in the basal layer. Today, DIS are
diagnosed at LM when round dilations or diffuse
widening of intercellular spaces are easily observed
using a 40× objective.60
DIS are not specific for GERD. Epithelial damage
brought on by even stress alone61 can dilate the in-
tercellular spaces. As Souza et al. suggested, refluxed
gastric juice can stimulate esophageal epithelial cells
to produce chemokines that eventually damage the
esophageal tissue;62 it is possible a similar mecha-
nism exists with other irritants.
DIS are also observed in EoE. The pattern is
nonetheless different. In GERD, the DIS are mainly
basal (Fig. 2A).59 In contrast,markedDIS in all three
layers are more often noted with EoE (Fig. 2B).63
All tests have significant limits. Today, there is no
gold standard method for the diagnosis of GERD.
The presence of DIS, when taken in context includ-
ing clinical presentation, DIS pattern, and other
histologic features, are a more sensitive marker of
GERD.59
9. Is the metastasizing potential of early
carcinoma dependent on extent of spread
through the MM?
Susan C. Abraham
suabraham@mdanderson.org
The anatomy of BE is unique. Unlikemucosal meta-
plasias occurring elsewhere in the gastrointestinal
tract, the metaplasia of BE involves both epithelium
and stroma. Stromal alterations include duplication
of the esophageal MM, hypertrophy and splaying of
a singleMM, extensionofMMbundles into the lam-
ina propria, lamina propria fibrosis, and benign en-
trapment of metaplastic ± dysplastic glands within
smooth muscle and fibrous tissue.10–12,64 Recogni-
tion of stromal alterations in BE began over three
decades ago, but only recently has attention focused
onhow thesemight affect the diagnosis, staging, and
prognosis of early EACs. These issues aremademore
important by the increasing incidence of EAC—
reported to be the fastest rising malignancy in the
United States—and by the widespread use of endo-
luminal therapies such as endoscopic mucosal re-
section for accurate staging and treatment of intra-
mucosal adenocarcinomas.
The first description of MM duplication in the
English literature appeared in 1981, in the case
report of a 71-year-old Japanese man with two
EACs and a double MM beneath columnar-lined
mucosa.9 The authors of that report surmised
that the deeper or outer MM represented original
esophageal MM, but that the inner layer arose from
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gastric MM. Two separate case reports mentioning
MM duplication in Japanese patients followed. In
1991, Takubo et al. published the first study of MM
duplication in BE, showing that it was both frequent
(present in seven of eight cases with BE) and highly
specific to BE (present in none of 352 cases without
BE).11 In a follow-up study from 1994, Nishimaki
et al. confirmed the high prevalence ofMMduplica-
tion in resection specimens with BE (14 of 15 cases,
93%) and asserted that dual MM—along with
specialized metaplastic columnar epithelium—was
“part of the specific histological changes character-
istic of Barrett’s esophagus.”12 Meanwhile, studies
fromCanada andEurope byRubio and colleagues in
1988 and 1991 emphasized other stromal changes in
BE—termed the musculo–fibrous anomaly—which
included hypertrophy and fibrosis of theMM, fibro-
sis of the lamina propria and submucosa, smooth
muscle ingrowth into the laminapropria, and subse-
quent entrapment, distortion, and cystic dilatation
of columnar-lined glands.10,64 These features were
felt to be morphologically akin to the mucosal pro-
lapse changes of solitary rectal ulcer syndrome and
could frequently result in difficulties differentiating
true invasion from benign glandular entrapment in
BE; however, MM duplication was not at that time
a recognized component of the musculo–fibrous
anomaly. Despite these multiple studies from the
1980s and 1990s of stromal alterations in BE,
this phenomenon actually received little notice in
histology textbooks or in clinical practice.
Depth of invasion is an important prognostic
factor in early EAC. Depth of invasion correlates
strongly with the risk of lymph node metastasis and
therefore is essential to the determination of therapy
(i.e., esophagectomy with lymph node dissection
versus endoscopicmucosal resectionwithout lymph
node removal). In a study from the University of
Texas M.D. Anderson Cancer Center, for example,
Liu et al. found lymph node metastases in 0% of
adenocarcinomas limited to the lamina propria,
12% of those in the MM, 8% in the superficial
submucosa, and 36% of the deep submucosa.65 But
can refinement of staging—that is, giving a precise
depth of invasion into lamina propria, inner MM,
space between dMM layers, or outer MM—yield
even more refined prognostic information?
This question is difficult to address because of
several factors. First, even though MM duplication
is overall very frequent in BE, it can be patchy. We
found that even among the 92%ofBE surgical resec-
tions and 66% of BE endoscopic mucosal resections
that contained MM duplication, the linear extent
of duplication varied widely, from <5% to >90%,
and with means of 48% and 43%, respectively.14,18
Therefore, studied cases have to include not only T1
adenocarcinomas, but those that occur in an area
of MM duplication. Second, determination of exact
depth of invasion (and even the presence of invasion
versus entrapment) can be difficult in cases with
marked MM hypertrophy or fibrous obliteration.
Finally, because of the relatively low risks of lymph
nodemetastases, distantmetastases, and death from
T1 adenocarcinomas, large numbers of cases are
needed to produce adequate events for statistical
analysis.
Nevertheless, three studies from the U.S. pop-
ulation including 30 patients with invasion into
dMM,14 82 patients with invasion into dMM,18
and 41 patients with invasion into dMM,16 have
addressed this question and the results—singly or
in combination—are clear (Table 2). Exact depth
of invasion into the dMM neither influences lymph
nodemetastasis nor does it appear to affect survival.
A theoretical basis for this finding is also supported
by studies that have shown similar densities of
lymphatic/vascular channels in the lamina propria
and in the space between dMM. The major cutoffs
in risk for T1 adenocarcinomas occur between
intramucosal invasion (including dMM) and
submucosal invasion, and between superficial sub-
mucosal invasion and deep submucosal invasion,
but not within intramucosal carcinoma itself.
In summary, the main reason to recognize MM
duplication vis-a`-vis EAC is to avoid the trap of
overstaging: Do not misinterpret invasion through
inner MM as submucosal invasion, and (worse yet)
do not misinterpret invasion into outer MM or
into thickened MM as invasion into muscularis
propria.
10. Are there molecular or
immunohistochemical tests, either singly
or in combination, that improve diagnosis
and management compared with
H&E-stained biopsies and surveillance?
Henry D. Appelman
appelman@umich.edu
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Table 2. Risk of lymph node metastasis in relation to depth of invasion into duplicated MM in the United States
Lymph node metastasis
+ Lymph nodes
No. invading
No. into duplicated
Study cases MM Depth of invasion Other findings
Abraham
et al.14
30 30 Inner MM 1/10 10% –
Between MM layers 1/12 8%
Outer MM 1/8 12%
Kaneshiro
et al.15
185 82 Lamina propria 1/68 1.5% Depth of invasion did not
predict survival
Inner MM 0/38 0%
Between MM layers 0/11 0%
Outer MM 0/33 0%
Submucosa (inner third) 3/35 9%
Estrella
et al.16
99 41 Lamina propria or inner
MM
1/28 4% In multivariate analysis, only
lymphovascular invasion
predicted recurrence-free
survival
“Duplicated MM space” 0/41 0%
Submucosa 10/30 33%
MM, muscularis mucosae.
This question is directed at two problems, the di-
agnosis of Barrett’s mucosa and the diagnosis of its
neoplastic complications.
Is there a better way to diagnose Barrett’s mucosa
than using H&E? Currently, the histologic diagnosis
of Barrett’s varies with where one lives. In all places,
there must be endoscopic evidence of Barrett’s, so
nothing has replaced the eyeballs of the endoscopist
for this part of the diagnosis. Also, regardless of
where one lives, biopsies from the endoscopic Bar-
rett’smusthave columnarmucosa.Pathologists have
no problem identifying columnarmucosa. So noth-
ing has replaced the eyeballs of the pathologist. If
you live in the United Kingdom and some other
countries, columnar mucosa of any type is needed
for the Barrett’s diagnosis, as long as the endoscopic
requirement is satisfied. If you live in the United
States and some other countries, this columnarmu-
cosa must have goblet cells to satisfy the Barrett’s
diagnosis. A mucin stain such as an Alcian blue will
bring out goblet cells, but finding them on H&E
is pretty easy, because in this stain, goblet cells are
gray or faintly blue compared with the gastric-type
columnar cells, which are pale pink. A mucin stain,
such as an Alcian blue, will stain the goblet cells an
intense blue, but this stain also uncovers cells that
might be misinterpreted as goblet cells. Specifically,
Barrett’s mucosae have columnar cells that contain
mucin in their apical cytoplasm that stains bluewith
the Alcian blue. These are not goblet cells but pe-
culiar columnar cells. These have even been given
the name of columnar blues, and so far, they have
not been considered to be a marker for intestinal
metaplasia.
Is there a better way to diagnose dysplasias and
carcinoma than by H&E-stained sections? First, the
criteria for the dysplasias are not clear-cut, so re-
producibility is poor, especially at the lower end
of the dysplasia spectrum. The diagnosis becomes
more reproducible at the higher end. We patholo-
gists are not so great in diagnosing dysplasias, es-
pecially low grade, so we need help. This is where
markersmight behelpful. Severalmarkers havebeen
studied in dysplasias including AMACR.67–69 This
is expressed in prostate and colon cancers. There
are a few published studies about this marker in
Barrett’s mucosa. In one study, 11% of low-grade
dysplasias, 64% of high-grade dysplasias, and 75%
of carcinomas stained positively. In another study,
there was staining even in 27% of those biopsies la-
beled as indefinite for dysplasia (IND), with 90%
in low-grade and 96% in high-grade dysplasia and
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also in 96% of carcinomas. The results of the third
study were between those other two. Therefore, it
is clear that these three studies used different diag-
nostic criteria for the different categories. The first
study upgraded the diagnoses whereas the third one
downgraded them. Furthermore, in these studies,
different specimens were used. Two of the studies
used biopsies and/or resections whereas the third
study used only resections. Diagnosing dysplasias in
resected specimens is not the important issue, be-
cause the esophagus has been resected. The impor-
tant dysplasia diagnoses are in biopsies, and none
of these studies give us much help with biopsies.
p53 is a tumor suppressor gene, a TF important in
cell cycle regulation. Its protein is nuclear, which
makes immunostains easy to interpret. In two stud-
ies, p53+ low-grade dysplasia was much more likely
to progress to higher grade dysplasia and carcinoma
than p53− low-grade dysplasia.69,70 This suggests
that the diagnosis of low-grade dysplasia by itself is
not as important as the diagnosis of low-grade dys-
plasia accompanied by positive p53 as an indication
of progression risk.
Other markers have been tested including c-myc
amplification, which was found only in high-grade
dysplasia and carcinoma, two of the easier diagnoses
by H&E.71 MUC2 was found in nondysplastic mu-
cosa whereas dysplasias were negative. MUC1 was
found in half the carcinomas.72 APC and p16 hy-
permethylation staining increased from negative to
low-grade dysplasia to high-grade and carcinoma,
and hypermethylation of both seemed to predict
progression.73 A number of other markers stud-
ies have been published, all of which conclude that
there are differences in expression in various types
of neoplastic and nonneoplastic Barrett’s mucosa.
A problem with all of these studies is the diagnos-
tic criteria used for dysplasias. Many referred to a
1983 paper by Riddell et al. dealing with dysplasias
in inflammatory bowel disease, but not in Barrett’s
mucosa. In some studies, the authors referred to the
use of “standard criteria” for dysplasias, but there
are no standard criteria. Remarkably, in some of
the marker studies, no histologic criteria were given
for the diagnoses. Regardless, in all these studies,
the diagnoses were made on H&E-stained sections
and the markers were related to those H&E-section
diagnoses.
In conclusion, the marker studies are based on
diagnoses made on slides stained with H&E. Be-
cause the diagnoses were already known, it is obvi-
ous that themarkers offered no better diagnostic in-
formation, possibly except for p53 staining of H&E-
diagnosed low-grade dysplasia. So, is there a better
way to manage Barrett’s than by diagnoses based
on H&E and appropriate endoscopic surveillance?
Some markers seem to correlate with progression,
but in order to determine if markers are valid de-
terminants of surveillance or treatment, long-term
studies are needed basing follow-up only on the
markers, not on diagnoses made by H&E. We ea-
gerly await such studies. At this moment, there are
no molecular or immunohistochemical tests that
improve diagnosis andmanagement comparedwith
H&E-stained biopsies and surveillance.
11. Does IHC have a role in: (1) grading of
neoplasia in Barrett’s esophagus? or (2)
defining the risk of progression to
adenocarcinoma?
Melissa P. Upton
mupton@uw.edu
Many investigators have looked for immunohisto-
chemicalmarkers thatmight improve the sensitivity
and specificity of detection of intraepithelial neo-
plasia (dysplasia) and adenocarcinoma over rou-
tine light microscopic examination of esophageal
biopsies in patients with BE. Potentially useful an-
tibodies include those recognizing p53, p16INK4A,
c-erbB2, cyclin D1, p27Kip1 EGFR, COX-2, -
catenin, Rab11a, CD1a, HER2, EGFR, SMAD4,
IMP3, Ki-67, Serpins, and AMACR.74 Although
individual studies have reported favorable results in
distinguishing low-grade (LGD) from high-grade
dysplasia (HGD), or HGD from EAC,75 repro-
ducibility of staining results has not been confirmed
when studied in multiple laboratories. Although
there is evidence that p53might be helpful to predict
patients who may progress to HGD,75 it is reported
to be expressed in approximately 5% of nondysplas-
tic BE. Therefore, although the rate of p53 expres-
sion is higher in dysplasia than in metaplasia, it is
not specific for dysplasia. In addition, evidence to
support consistently positive andnegativepredictive
values of any potentially useful marker awaits larger
series. Therefore, at the current time, few laborato-
ries are routinely applying IHC in the evaluation of
esophageal biopsies for neoplasia in BE.
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Table 3. AMACR immunohistochemistry: summary of four studies66–68,77 showing percentage of cases expressing
AMACR and the sensitivity of the stain in each study by histology category
Grade % Positive % Sensitivity % Specificity
BE no dysplasia 0 100
Indefinite for dysplasia 0, 22, 21, 27 22
Low-grade dysplasia 11, 18, 38, 90 38, 91
High-grade dysplasia 60, 64, 81, 96 64, 81, 96 100
EAC 67, 72, 75, 96 72, 96 100
AMACR, -methylacyl coenzyme A racemase; BE, Barrett esophagus; EAC, esophageal adenocarcinoma.
Does a menu of stains offer increased value
over use of a single immunohistochemical stain?
Van Dekken et al. applied a panel including epi-
dermal growth factor receptor (EGFR), ERBB2
(HER2/neu),MYC,CDKN2A (p16), SMAD4,MET,
CCND1 (cyclin D1), CTNNB1 (-catenin), and
TP53 (p53), comparing expression in 86 cases along
the spectrum from BE to EAC. Among antibod-
ies with statistically significant results (P < 0.001),
-catenin distinguished BE from LGD, and both
cyclin D1 and p53 distinguished LGD from HGD.
Despite this degree of significance, fewer than 25%
of LGD cases showed intense staining for -catenin,
andonly45%of casesofHGDexpressed cyclinD1.76
One of the better-studied markers, AMACR, is
a mitochondrial peroxisomal enzyme expressed in
colonic adenocarcinomas but not in normal colonic
epithelium. Esophageal biopsies from patients with
BE have been stained for AMACR by several groups,
whoexamined cases of nondysplasticBE, IND,LGD,
HGD, and EAC. Table 3 summarizes four studies
and shows the percentage of cases in each histolog-
ical category that express AMACR and also the sen-
sitivity and specificity, when reported. Of note, all
groups reported uniform absence of reactivity for
BE without dysplasia; therefore, AMACR staining
may be helpful in cases concerning possible dys-
plasia. Although a definite trend was seen in all
studies, there was considerable variation in stain-
ing in each neoplastic category; the percentage of
IND cases that expressed AMACR ranged from 0%
to 29%. This may reflect differences in histological
classification of the study set, in terms of the inves-
tigators’ thresholds for assigning grade, as well as
differences in thresholds for positive results.67–69,77
INDcaseswithAMACRexpressionweremore likely
to progress to EAC than negative IND cases, but the
positive predictive value was only modest (0.44).77
Mostof the above stains are expressed inneoplasia
but not in nonneoplastic BE. In contrast, Beclin-1
has a central role in autophagy and is upregulated
with bile acid exposure and BE, but downregulated
with neoplastic progression.Of note, bile acid reflux
is reported in 22%of patients with esophagitis but is
more common in BE, affecting 54% of patients with
BE and 76% of patients with EAC. Loss of nuclear
expression of Beclin-1 is seen in LGD, HGD, and
in EAC, with statistically significant differences in
staining intensity; however, there is some overlap
in RNA levels of expression between nonneoplastic
BE and EAC.78 Beclin-1 may be useful for inclusion
in a staining menu, as it is desirable for a panel to
combine markers that are expected to be positive
with markers that are typically negative.
Several fundamental challenges limit clinical
applicability of currently reported immunohisto-
chemical markers. First, each study used a set of
cases that were classified histologically; however,
histological classification is imperfect, given inter-
observer variability.77 As seen with AMACR, the
sensitivity and specificity of a marker varies among
studies, and this variation may reflect differences
in interpretation and classification of the study set,
rather than marker utility. Different studies also
used different thresholds for positive results, with
no consensus standard. Case numbers are relatively
small in most studies. There is no single pathway
from normal to cancer. It is even controversial
whether HGD evolves from LGD, or whether it
represents a distinctive form of intraepithelial
neoplasia, with potentially distinctive etiology
and expression profiles. It is also well known that
even within a single histological category or grade,
individual neoplasms often have different expres-
sion profiles. In Barrett’s neoplasia each group
(LGD, HGD, intramucosal adenocarcinoma, and
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adenocarcinoma that has invaded the submucosa)
is heterogeneous, comprising a range of histological
patterns and cytological phenotypes, with different
genetic signatures and transcription profiles. In
the vast majority of studies, there is no long-term
follow-up to correlate clinical outcomes with im-
munohistochemical results. Validation of markers
for utility in diagnosis and prognosis remains to
be done. And finally, cost-effectiveness studies are
needed to define if addition of IHC in the grading of
Barrett neoplasia adds value over review by a second
experienced pathologist, which is the current Amer-
ican College of Gastroenterology recommendation.
In conclusion, clear differences in immunohis-
tochemical expression of specific antigens are seen
in different grades in some, but not in all, cases of
Barrett’s neoplasia.Thesefindings areuseful and im-
portant contributions to our understanding of the
process of neoplastic development and associated
altered protein expression. Applying these stains in
a research setting will continue to inform our un-
derstanding of the biology of Barrett’s neoplasia. It
remains unclear if immunohistochemical staining
adds clinical value over the gold standard of histo-
logical grading and review by a second experienced
pathologist. Currently, no single marker or panel
is clearly predictive of risk to progression to EAC.
Largermulticenter studies including a range of cases
areneeded toprovidedefinitive evidence for theutil-
ity and cost-effectiveness of immunohistochemical
staining in routine clinical diagnostic work.
12. What are the roles of CDX1 and CDX2
in squamous and cardiac mucosa?
Andrew M. Bellizzi
andrew-bellizzi@uiowa.edu
Introduction
The TFs CDX1 and CDX2, human homologues of
the Drosophila homeobox gene Caudal, participate
in intestinal development and patterning andmain-
tain the intestinal phenotype. They are normally ex-
pressed in the tubal gut distal to the stomach and
direct their effects through numerous target genes.
Given the fact that Barrett mucosa is intestinalized,
investigators correctly anticipated CDX1/2’s rele-
vance. This brief commentary here will discuss (1)
knockout and transgenic mouse models that high-
light the critical functions of CDX, (2) expression
of these TFs in human esophageal biopsy material,
and (3) experiments in cell cultures and cell lines in
which conditions mimicking GERD are established
or CDX1 or CDX2 are transfected. It will conclude
with reference to more recent studies suggesting
that, although CDX expression appears critical in
the establishment and maintenance of BE, it is not
the sole determinant.
Knockout and transgenic mouse models
The Cdx1−/− mouse has no gut phenotype, at-
tributed to the protein’s functional redundancy.
Cdx2−/− embryos fail to implant, as Cdx2 is
critical to the developing trophectoderm. The
Cdx2+/− mouse develops metaplastic, squamous-
lined polyps in the ileocecal region.79 The adjacent
mucosa is characterized by the sequential interpo-
sition of cardiac, cardio-oxyntic, oxyntic, and small
intestinal mucosa. The polyps occur in areas of hap-
loinsufficiency, with the gut reverting to the default
foregut (squamous) differentiation program. In the
developing embryo, a morphogenic milieu exists to
direct the intercalary growth described earlier. A
more recent Cdx2 conditional knockout overcomes
the implantation block.80 The tubal gut ends as a
blind pouch at the cecum and is lined by squamous
epithelium.
A transgenic mouse model in which Cdx2
is placed under the H+/K+-ATPase  subunit
promoter (normally expressed in gastric parietal
cells) results in complete intestinalization of the
stomach.81 Although morphologically normal at
birth, intestinalized crypts are detected at day 19,
and at day 37 the oxyntic mucosa is largely replaced
by crypts composed of goblet, absorptive, and en-
teroendocrine cells. This result was independently
validated by a group who placed Cdx2 under the
Foxa3 promoter, and, although the Cdx1 knockout
mouse has no intestinal phenotype, forced Cdx1
expression in the stomach also leads to profound
intestinalization.
CDX expression in esophageal biopsy
material
As first reported by Phillips et al. in 2003, several
groups have shown CDX2 protein expression, as
detected by IHC, in virtually all biopsies of Barrett’s
epithelium (i.e., columnar epithelium with gob-
let cells proximal to the anatomic GEJ) (Fig. 3).82
CDX2 expression was also found in 30% (20/62) of
esophageal cardia-type mucosal samples (i.e., with-
out goblet cells), suggesting that that epithelium is at
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Figure 3. CDX2 expression in BE: CDX2 is expressed by
the columnar epithelium in virtually all Barrett biopsies (note
the goblet cells in this example) and 30–40% of biopsies of
esophageal metaplastic columnar epithelium without goblet
cells (immunoperoxidase, original magnification 200×).
least partially intestinalized. CDX2 expression is not
detected in cardia-type epithelium in the stomach.
Utilizing qualitative reverse transcriptase–
polymerase chain reaction (RT–PCR), Eda et al.
found CDX2mRNA in squamous mucosal biopsies
from 10 of 15 (67%) GERD patients with mucosal
breaks and zero of five normal controls; CDX1
mRNA was not detected.83 Although Moons
and colleagues did not detect CDX2 protein
expression (by IHC) in 40 biopsies of esophageal
squamous mucosa taken from GERD patients,
they did find small amounts of CDX2 mRNA in
6 of 19 (33%) biopsies taken from 5 cm above
the neo-squamocolumnar junction in Barrett’s
patients.84
Experiments in cell lines and keratinocyte
cell cultures
BE arises in the setting of gastroduodenal reflux
and inflammation. Investigators have attempted to
model BE by exposing cell lines and cell cultures to
low pH, bile acids, and/or inflammatory cytokines,
which have been found to induce the expression
of CDX1/2. In addition, the more direct effects of
CDX1/2 are assessed in transfection experiments.
This line of investigation has also served to highlight
the importance of upstream NF-B signaling and
epigenetic transcriptional regulation.
In one example, Kazumori et al. showed that
different bile acids variably activated the CDX2
promoter in cell lines, with DHCA and CA
achieving the greatest induction.85 The effect was
abrogated by mutation of NF-B–binding sites in
the CDX2 promoter. When primary rat esophageal
keratinocyte cell cultures were incubated with ei-
ther DHCA or CA, Cdx2 expression was induced in
a dose-dependent manner. Finally, Cdx2 transfec-
tion of the cell culture resulted in expression of the
intestine-specific apomucin MUC2.
Wongand colleagues performeda similar series of
experiments, with their key contribution being the
demonstrationof the importanceof themethylation
status of gene promoters.86 Using bisulfite sequenc-
ing, they showed that although the CDX1 promoter
was completely methylated in normal esophageal
squamous and gastric corpus mucosa, it was un-
methylated innormal colonicmucosa anddemethy-
lated in BE. Although the inflammatory cytokine
TNF- had no effect on CDX1 mRNA expression
in cell lines with a normally methylated CDX1 pro-
moter, treatment with the demethylating agent 5-
aza-2′-deoxycytidine rendered them responsive.
CDX expression alone is insufficient to
account for BE
Given the striking phenotype of the transgenic
mouse models in which Cdx2 is expressed in
the stomach, one might assume that a transgenic
mouse in which Cdx2 is expressed in the esopha-
gus might provide an excellent model of BE. John
Lynch’s group at the University of Pennsylvania
has produced such a mouse, in which Cdx2 is ex-
pressed in squamous epithelium using the keratin-
14 promoter.87 The mouse expresses Cdx2 in basal
keratinocytes, which is associated with reduced pro-
liferation, formation of DIS, reduced cell–cell adhe-
sion, and, ultrastructurally, assumption of a more
secretory-like phenotype (reduced keratin bundles,
increased endoplasmic reticulum). Goblet cells are
not induced, though,nor areCdx2 targets likeMuc2,
sucrase isomaltase, and alkaline phosphatase. Al-
though treatment with 5′-azacytadine did not alter
the model’s morphology, it increased Cdx2 mRNA
levels 250-fold and resulted in expression of the
Cdx2 targets Cdx1, keratin-18, and SLC26A3/DRA.
The authors concluded that Cdx2 expression alone
is insufficient toproduce the full Barrett’s phenotype
and that this is in part due to epigenetic regulation
of the adult genome. Furthermore, although Cdx2
expression results in reducedproliferation, that phe-
notype must be overcome by some other factor(s),
as BE, even without dysplasia, is proliferative.
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Gene expression microarrays have identified
hundreds of genes (including CDX1) differentially
expressed in BE compared to squamous-lined
esophagus. Rebecca Fitzgerald’s group has recently
focused on the HOXB gene cluster (like CDXs,
these TFs also contain the homeobox domain).88
HOXB5, HOXB6, and HOXB7 are upregulated
in BE, and transfection experiments involving a
human esophagus–derived cell line demonstrated
upregulation of the intestinal markers keratin
20, MUC2, and villin (but not CDX2). They also
found that expression of these HOXs was related
to specific activating histone modifications in their
gene promoters and to chromatin decompaction.
Summary
BE is characterized by the replacement of a dif-
ferentiated squamous epithelium with a columnar
epithelium that is intestinalized. CDX2, a TF that
is both a marker of intestinal differentiation and a
significant player in directing the intestinal differen-
tiation program, is expressed in virtually all Barrett’s
biopsies. In cell lines and keratinocyte cell cultures,
experimental conditions mimicking GERD pro-
mote CDX1 and CDX2 expression and transfection
experiments induce the production of CDX targets.
This research has also highlighted the importance
of upstream NF-B signaling and epigenetic
regulation of these TFs by promoter methylation.
Although transgenic mouse models in which
Cdx1 or Cdx2 are constitutively expressed in the
stomach demonstrate profound intestinalization, a
mouse in which Cdx2 expression is placed under
the keratin-14 promoter fails to fully recapitulate
the Barrett’s phenotype. Treatment of the mouse
with a demethylating agent advances the columnar
phenotype, again highlighting the importance of
epigenetic regulation. Expression microarrays have
identified hundreds of genes differentially expressed
in BE relative to esophageal squamous epithelium.
These include three HOXB family TFs, which, in
transfection experiments, are also able to induce the
expression of intestine-specific proteins. Increased
expression of these HOXs occurs in the setting of
activating histone modifications and chromatin de-
compaction.
A model has emerged in which gastroduodenal
reflux and inflammatory cytokines participate in
creating an environment favorable to the expression
of key TFs, including but not limited to CDX1/2,
which direct intestinal differentiation. Key features
of that favorable environment include NF-B sig-
naling, promoter demethylation, histone modifica-
tion, and chromatin decompaction.
13. What is the role of desmosomal
cadherins and lectins in squamous and
cardiac mucosa?
Helmut Neumann, Markus F. Neurath,
and Michael Vieth
helmut.neumann@uk-erlangen.de
Desmosomes represent adhesive intercellular junc-
tion proteins. Their adhesion molecules are the
desmosomal cadherins desmoglein and desmo-
collin. Both adhesion molecules are widely
expressed in the tissue, including the stratified squa-
mous epithelium, the skin, salivary glands, hair fol-
licles, prostate, and testis. Moreover, it was shown
that desmosomal cadherins are involved in vari-
ous pathological processes like pemphigus folia-
ceous, mucocutaneous pemphigus vulgaris, pem-
phigus vulgaris, and paraneoplastic pemphigus.89
Focusing on esophageal squamous epithelium,
desmoglein 1 and desmocollin 1 are mainly ex-
pressed in the superficial parts, whereas desmoglein
2 and desmocollin 2 are only found in the basal
cell layer. Contrary, the expression of desmoglein 3
and desmocollin 3 is mostly restricted to the basal
epithelial layer while there is only a weak expres-
sion of these desmosomal cadherins in the super-
ficial layers of esophageal squamous epithelium.
One recent study evaluated the gene expression of
desmoglein 1, desmoglein 2, and desmoglein 3 in
the esophageal mucosa.90 The authors described a
uniform upregulation of desmosomal genes in the
esophageal mucosa of patients with GERD, thereby
supporting the concept of changes in the desmoso-
mal compartment in thepathogenesis ofGERD.The
same group assessed different desmosomal compo-
nents in cardia mucosa in relation to GERD and
Helicobacter pylori infection and found an upregu-
lation of desmoglein 2 in cardia mucosa of patients
with GERD.91 They concluded that these findings
underline the concept that changes in the desmoso-
mal compartment contribute to the pathogenesis of
GERD in the cardia mucosa.
Lectins are a structurally heterogeneous group of
carbohydrate-binding proteins, which were found
to be highly specific for their respective sugar
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moieties. Lectins have a distinct role in biologi-
cal recognition phenomena including regulation of
cell adhesion.92 Based on their binding specificity,
five distinct classes of lectins can be differentiated.
Various studies have already shown that lectins are
present in normal, inflamed, and neoplastic mu-
cosa, but composition may change according to the
underlying condition.
In 1999, Poorkhalkali and coworkers analyzed
12 different lectins to investigate the differences in
glycoconjugate production among different mam-
malian species.93 In general, the strongest lectin
staining was found in the stratum superficiale and
the weakest staining in the stratum germinativum.
Interestingly, superficial damage to the rabbit esoph-
agus epithelium after exposure to pepsin/HCl pro-
duced a considerable decrease in electrical resis-
tance and a decreased staining of the esophageal
epithelium with selected lectins. For example, this
effect was shown for the lectins WGA and UEA-
II. Pretreatment of the esophageal mucosa with a
compound with protective properties (sucrose oc-
tasulfate) prevented to some extent the decrease
in resistance and lectin staining. Recently, lectin-
binding patterns were evaluated in patients with
GERD and Heliobacter pylori infection.94 Therefore,
88 patients were included and lectin-binding pat-
terns were examined immunohistochemically at the
squamocolumnar junction and in squamous and
columnar-lined epithelium. Lectin binding was sig-
nificantly reduced for the lectins UEA-I, DBA, and
PNA in columnar-lined epithelium, and for DBA in
the squamous epithelium of patients with GERD,
respectively. H. pylori infection was associated with
reduced PNA and DBA binding to the deep glan-
dular mucosa of columnar-lined epithelium and
surface squamous epithelium, respectively. More
recently, the same group analyzed the binding pat-
tern of different lectins at the GEJ in patients with
NERD, ERD, and BE.95 One hundred and twenty-
two patients were included, and staining patterns
of lectins were semiquantitatively evaluated using
an immunohistochemical score. It was found that
in patients with BE, lectin binding of UEA-I and
DBA were significantly decreased at the superficial
and deep glandular body. Comparisons of lectin-
staining scores between GERD and BE revealed sig-
nificant increases of UEA-I in both the stratum
superficiale and stratum spinosum of squamous ep-
ithelium in patients with BE. No difference was ob-
served between patients with GERD and controls.
As lectin–UEA-I–binding proteins were specifically
increased in the squamous epithelium of patients
with BE, the authors concluded that UEA-I may
serve as a potential marker for BE, especially in pa-
tients with short-segment BE. Nevertheless, further
validation studies of this promising approach are
still anticipated.Very recently, itwas shown that cell-
surface glycans are altered in the progression from
BE to adenocarcinoma and lead to specific changes
in lectin-binding patterns.96 The binding of wheat
germ agglutinin to human tissue was determined to
be specific. By usingmolecular imaging, this specific
binding was validated by successful visualization of
high-grade dysplastic lesions in BE, which were pre-
viously not detectable by conventional endoscopy.
In conclusion, proteins within the intercellular
spaces can be further characterized (e.g., cadherins,
lectins). Various studies have shown that the expres-
sion of cadherins and lectins is altered in GERD and
BE. Currently, these markers are only of scientific
interest, but further characterization will lead to a
better understanding of early damage due to reflux
disease.
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